232 related articles for article (PubMed ID: 31149909)
1. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
2. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
3. Extravesical Pagetoid Spread of Urothelial Carcinoma in Situ. A Report of Five Cases.
Akgul M; Bomeisl PB; MacLennan GT
Anal Quant Cytopathol Histpathol; 2015 Dec; 37(6):364-8. PubMed ID: 26860012
[TBL] [Abstract][Full Text] [Related]
4. Progression of urothelial carcinoma in situ of the urinary bladder: a switch from luminal to basal phenotype and related therapeutic implications.
Barth I; Schneider U; Grimm T; Karl A; Horst D; Gaisa NT; Knüchel R; Garczyk S
Virchows Arch; 2018 May; 472(5):749-758. PubMed ID: 29654370
[TBL] [Abstract][Full Text] [Related]
5. Morphologic expressions of urothelial carcinoma in situ: a detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion.
McKenney JK; Gomez JA; Desai S; Lee MW; Amin MB
Am J Surg Pathol; 2001 Mar; 25(3):356-62. PubMed ID: 11224606
[TBL] [Abstract][Full Text] [Related]
6. Urine cytology findings in patients with biopsy-confirmed urothelial carcinoma in situ with plasmacytoid features.
Nichols MM; Reynolds JP; McKenney JK; Nicolas MM; McIntire PJ; Policarpio-Nicolas MLC
Cancer Cytopathol; 2021 Oct; 129(10):798-804. PubMed ID: 33900681
[TBL] [Abstract][Full Text] [Related]
7. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic Molecular Subclassification of Urothelial Carcinoma of the Bladder: Are We Finally there?
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM
Adv Anat Pathol; 2019 Jul; 26(4):251-256. PubMed ID: 31188799
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
[TBL] [Abstract][Full Text] [Related]
10. Urothelial carcinoma in situ: diagnostic update.
McKenney JK
Pathology; 2021 Jan; 53(1):86-95. PubMed ID: 33234229
[TBL] [Abstract][Full Text] [Related]
11. Carcinoma in situ of the urinary bladder: review of clinicopathologic characteristics with an emphasis on aspects related to molecular diagnostic techniques and prognosis.
Nese N; Gupta R; Bui MH; Amin MB
J Natl Compr Canc Netw; 2009 Jan; 7(1):48-57. PubMed ID: 19176205
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases.
Guo CC; Fine SW; Epstein JI
Am J Surg Pathol; 2006 Jul; 30(7):883-91. PubMed ID: 16819332
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive papillary urothelial neoplasia (NIPUN): Renaming cancer.
Jones TD; Cheng L
Urol Oncol; 2021 May; 39(5):286-290. PubMed ID: 35550107
[TBL] [Abstract][Full Text] [Related]
14. Urothelial dysplasia of the bladder: diagnostic features and clinical significance.
Lopez-Beltran A; Montironi R; Vidal A; Scarpelli M; Cheng L
Anal Quant Cytopathol Histpathol; 2013 Jun; 35(3):121-9. PubMed ID: 24344498
[TBL] [Abstract][Full Text] [Related]
15. Molecular Pathology of Urothelial Carcinoma.
Al-Ahmadie H; Netto GJ
Clin Lab Med; 2024 Jun; 44(2):181-198. PubMed ID: 38821640
[TBL] [Abstract][Full Text] [Related]
16. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
[TBL] [Abstract][Full Text] [Related]
17. Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases.
Sangoi AR; Falzarano SM; Nicolas M; McKenney JK
Am J Surg Pathol; 2019 Dec; 43(12):1638-1643. PubMed ID: 31368912
[TBL] [Abstract][Full Text] [Related]
18. Amyloidosis of the bladder and association with urothelial carcinoma: report of 29 cases.
Sirohi D; Gandhi J; Amin MB; Luthringer DJ
Hum Pathol; 2019 Nov; 93():48-53. PubMed ID: 31425694
[TBL] [Abstract][Full Text] [Related]
19. Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections.
Poropatich K; Yang JC; Goyal R; Parini V; Yang XJ
Diagn Pathol; 2016 Jun; 11(1):57. PubMed ID: 27357719
[TBL] [Abstract][Full Text] [Related]
20. Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk Quanticyt.
van Rhijn BW; van der Poel HG; Boon ME; Debruyne FM; Schalken JA; Witjes JA
Urology; 2000 Mar; 55(3):363-7. PubMed ID: 10699611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
